• Bradycardia After Sofosbuvir and Daclatasvir in 2 Patients Receiving Amiodarone

Bradycardia After Sofosbuvir and Daclatasvir in 2 Patients Receiving Amiodarone

Two patients receiving treatment with amiodarone developed bradycardia within 2 hours after taking sofosbuvir and daclatasvir  for hepatitis C, researchers report in the November issue of Gastroenterology. Patients treated with amiodarone should be continuously monitored within the first 48 hours after receiving these hepatitis C drugs, say the authors of the Brief Report. Sofosbuvir and

Read more
  • Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more
  • How Do NS5A Inhibitors Prevent HCV Replication?

How Do NS5A Inhibitors Prevent HCV Replication?

Researchers have uncovered the mechanisms of drugs that inhibit the hepatitis C virus (HCV) non-structural protein 5A (NS5A), described in the August issue of Gastroenterology. In a quantitative analysis of the kinetics of NS5A inhibitors, David R. McGivern et al.  show that these agents rapidly inhibit intracellular assembly of virions and

Read more